195 related articles for article (PubMed ID: 29909874)
1. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
[TBL] [Abstract][Full Text] [Related]
2. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.
Barua S; Greenwald R; Grebely J; Dore GJ; Swan T; Taylor LE
Ann Intern Med; 2015 Aug; 163(3):215-23. PubMed ID: 26120969
[TBL] [Abstract][Full Text] [Related]
3. Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.
Ooka K; Connolly JJ; Lim JK
Am J Gastroenterol; 2017 Jun; 112(6):828-832. PubMed ID: 28374816
[No Abstract] [Full Text] [Related]
4. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.
Litzroth A; Suin V; Wyndham-Thomas C; Quoilin S; Muyldermans G; Vanwolleghem T; Kabamba-Mukadi B; Verburgh V; Jacques M; Van Gucht S; Hutse V
BMC Public Health; 2019 Jan; 19(1):39. PubMed ID: 30621662
[TBL] [Abstract][Full Text] [Related]
5. Restricted Access: State Medicaid Coverage of Sofosbuvir Hepatitis C Treatment.
Tumber MB
J Leg Med; 2017; 37(1-2):21-64. PubMed ID: 28910222
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
[TBL] [Abstract][Full Text] [Related]
7. Utilization, reimbursement, and price trends for Hepatitis C virus medications in the US Medicaid programs: 2001-2021.
Gari MH; Alsuhibani A; Alashgar A; Guo JJ
Explor Res Clin Soc Pharm; 2023 Dec; 12():100383. PubMed ID: 38145237
[TBL] [Abstract][Full Text] [Related]
8. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
9. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
Girardin F; Goossens N; Vernaz N; Negro F
Rev Med Suisse; 2015 Sep; 11(484):1610-2, 1614-6. PubMed ID: 26502622
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
11. Cost burden of hepatitis C virus treatment in commercially insured patients.
Lu CY; Ross-Degnan D; Zhang F; LeCates R; Lupton C; Sherman M; Wagner A
Am J Manag Care; 2019 Dec; 25(12):e379-e387. PubMed ID: 31860232
[TBL] [Abstract][Full Text] [Related]
12. Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.
Davey S; Costello K; Russo M; Davies S; Lalani HS; Kesselheim AS; Rome BN
JAMA Health Forum; 2024 Apr; 5(4):e240302. PubMed ID: 38578628
[TBL] [Abstract][Full Text] [Related]
13. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
[TBL] [Abstract][Full Text] [Related]
14. Treating Medicaid patients with hepatitis C: clinical and economic impact.
Younossi Z; Gordon SC; Ahmed A; Dieterich D; Saab S; Beckerman R
Am J Manag Care; 2017 Feb; 23(2):107-112. PubMed ID: 28245654
[TBL] [Abstract][Full Text] [Related]
15. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.
Kabiri M; Chhatwal J; Donohue JM; Roberts MS; James AE; Dunn MA; Gellad WF
Healthc (Amst); 2017 Sep; 5(3):105-111. PubMed ID: 27932263
[TBL] [Abstract][Full Text] [Related]
16. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use.
Auty SG; Shafer PR; Dusetzina SB; Griffith KN
JAMA Health Forum; 2021 Aug; 2(8):e212285. PubMed ID: 35977199
[TBL] [Abstract][Full Text] [Related]
17. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
18. HIV/HCV Co-infection: Overcoming Barriers to Treatment.
Gross C; Akoth E; Price A; Kattakuzhy S; Silk R; Rosenthal E
J Assoc Nurses AIDS Care; 2016; 27(4):524-9. PubMed ID: 26996983
[TBL] [Abstract][Full Text] [Related]
19. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
Marshall AD; Cunningham EB; Nielsen S; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Seguin-Devaux C; Flisiak R; Foster GR; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancorienė L; Jarcuska P; Kåberg M; Kostrikis LG; Makara M; Maimets M; Marinho RT; Matičič M; Norris S; Ólafsson S; Øvrehus A; Pawlotsky JM; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J;
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):125-133. PubMed ID: 28986139
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.
Chhatwal J; Wang X; Ayer T; Kabiri M; Chung RT; Hur C; Donohue JM; Roberts MS; Kanwal F
Hepatology; 2016 Nov; 64(5):1442-1450. PubMed ID: 27015107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
